专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140044799A1 MOLECULAR SIGNATURE OF CUTANEOUS PIGMENTARY SPOTS, ASSOCIATED WITH THE ORGANIZATION OF THE EXTRACELLULAR MATRIX 审中-公开
标题翻译：与组织细胞基质相关的胡萝卜色素分子标记
公开(公告)号：US20140044799A1
公开(公告)日：2014-02-13
申请号：US14112111
申请日：2012-04-20
申请人： Francoise Bernerd , Christine Duval , Olivier De Lacharriere , Stephanie Nouveau , Xavier Marat
发明人： Francoise Bernerd , Christine Duval , Olivier De Lacharriere , Stephanie Nouveau , Xavier Marat
IPC分类号： A61K38/16 , A61K36/48 , C12Q1/68 , A61K31/7028 , A61K31/155 , A61K31/41 , A61K31/4196 , A61K31/381 , A61K31/192 , A61K35/32 , A61K31/4365
CPC分类号： A61K38/16 , A61K31/155 , A61K31/192 , A61K31/381 , A61K31/41 , A61K31/4196 , A61K31/4365 , A61K31/7028 , A61K35/32 , A61K36/48 , C12Q1/6876 , C12Q1/6883 , C12Q2600/106 , C12Q2600/148 , C12Q2600/158
摘要： The present invention concerns a molecular signature of cutaneous pigmentary spots, comprising the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2, and various applications of this signature. In particular, the invention concerns a method for characterizing a known or suspected pigmentary spot in a human being, comprising comparing the levels of expression in skin samples obtained from said spot and from adjacent undamaged skin, of at least one dermal gene linked to matrix remodelling or to its extracellular proteoglycan and glycoprotein components, selected from the list constituted by the genes MXRA5, LYZ, CTSL2, PLAU, TIMP1, EFEMP1, ECM1, ASPN, HS3ST6, PAPLN, CHSY1 and FLRT2. The invention also concerns methods for evaluating the efficacy of a pigmentary spot treatment, cosmetic and therapeutic methods for the treatment of pigmentary spots, and various modulators for said genes, and their use.
摘要翻译：本发明涉及皮肤色素斑点的分子标记，其包含基因MXRA5，LYZ，CTSL2，PLAU，TIMP1，EFEMP1，ECM1，ASPN，HS3ST6，PAPLN，CHSY1和FLRT2，以及该特征的各种应用。特别地，本发明涉及用于表征人中已知或疑似的色素斑点的方法，其包括比较从所述斑点和相邻未损伤的皮肤获得的皮肤样品中至少一种与基质重塑有关的真皮基因的表达水平或选自由基因MXRA5，LYZ，CTSL2，PLAU，TIMP1，EFEMP1，ECM1，ASPN，HS3ST6，PAPLN，CHSY1和FLRT2构成的细胞外蛋白多糖和糖蛋白成分。本发明还涉及用于评价颜料斑点处理，用于治疗色素斑点的化妆品和治疗方法以及所述基因的各种调节剂及其用途的功效的方法。

2. 发明授权

US07351699B1 Use of DHEA or precursors or metabolic derivatives thereof as a depigmenting agent 失效
标题翻译：使用DHEA或其前体或其代谢衍生物作为脱色剂
公开(公告)号：US07351699B1
公开(公告)日：2008-04-01
申请号：US09686997
申请日：2000-10-12
申请人： Olivier De Lacharriere , Stephanie Nouveau
发明人： Olivier De Lacharriere , Stephanie Nouveau
IPC分类号： A61K31/56 , A61K8/02 , A61K8/18
CPC分类号： A61Q19/02 , A61K8/35 , A61K8/368 , A61K8/37 , A61K8/40 , A61K8/466 , A61K8/4946 , A61K8/585 , A61K8/63 , A61Q19/00
摘要： The use of DHEA or at least one of its biological precursors or of its metabolic derivatives in or for the manufacture of a composition for topical application to the skin, as a pigmentation regulator for the skin or its superficial growths, especially as a depigmenting and/or bleaching agent for the skin, in particular in the treatment of pigmentation marks, and as a pro-pigmenting agent for superficial body growths.
摘要翻译：特别是作为色素沉淀和/或染色剂使用DHEA或其生物前体或其代谢衍生物中的至少一种用于或用于制造用于皮肤局部施用的组合物，作为皮肤或其表面生长的色素调节剂，或漂白剂，特别是用于治疗色素沉着痕迹，以及作为表皮体生长的前色素剂。

3. 发明授权

US06509014B1 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema 有权
标题翻译：包含用于治疗皮肤发红/红斑痤疮/谨慎性红斑的CGRP拮抗剂的治疗/美容组合物
公开(公告)号：US06509014B1
公开(公告)日：2003-01-21
申请号：US09318237
申请日：1999-05-25
申请人： Olivier De Lacharriere , Lionel Breton
发明人： Olivier De Lacharriere , Lionel Breton
IPC分类号： A61K39395
CPC分类号： A61K39/3955 , A61K38/225 , Y10S424/809
摘要： Skin redness, rosacea and/or discreet erythema afflicting a mammalian, notably human patient, are therapeutically treated by administrating to such patient a therapeutically/cosmetically effective amount of at least one CGRP antagonist, advantageously in combinatory immixture with at least one antagonist of a neuropeptide other than CGRP, e.g., a substance P antagonist, and/or at least one inflammation mediator antagonist.
摘要翻译：影响哺乳动物，特别是人类患者的皮肤红肿，红斑痤疮和/或谨慎性红斑，通过向该患者施用治疗/化妆有效量的至少一种CGRP拮抗剂，有利地与至少一种神经肽拮抗剂的组合性固定除CGRP外，例如物质P拮抗剂和/或至少一种炎症介质拮抗剂。

4. 发明授权

US06241993B1 Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin 失效
公开(公告)号：US06241993B1
公开(公告)日：2001-06-05
申请号：US09087803
申请日：1998-06-01
申请人： Lionel Breton , Olivier De Lacharriere
发明人： Lionel Breton , Olivier De Lacharriere
IPC分类号： A61K748
CPC分类号： A61K8/64 , A61K8/37 , A61K8/63 , A61K8/671 , A61K2800/70 , A61K2800/75 , A61Q1/14 , A61Q17/00 , A61Q17/02 , A61Q19/00 , A61Q19/004 , A61Q19/005 , A61Q19/08 , Y10S514/844 , Y10S514/846 , Y10S514/936 , Y10S514/944
摘要： Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the &agr;-hydroxy and &bgr;-hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one bradykinin antagonist.

5. 发明授权

US06169069A Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids 失效
标题翻译：包含用于治疗眼睛或眼睑的CGRP拮抗剂的治疗/化妆品组合物
公开(公告)号：US06169069A
公开(公告)日：2001-01-02
申请号：US08623576
申请日：1996-03-28
申请人： Olivier De Lacharriere , Lionel Breton
发明人： Olivier De Lacharriere , Lionel Breton
IPC分类号： A61K3800
CPC分类号： A61K38/225 , A61K39/3955 , Y10S514/844
摘要： Ocular and/or palpebral pruritus and/or ocular and/or palpebral pain and/or ocular and/or palpebral dysaesthesia afflicting a mammalian, notably human patient, are therapeutically treated by administering to such patient a therapeutically/cosmetically effective amount of at least one CGRP antagonist, advantageously in combinatory immixture with at least one antagonist of a neuropeptide other than CGRP, e.g., a substance P antagonist, and/or at least one inflammation mediator antagonist; the subject compositions are also well suited for making up and/or caring for human eyes, eyelashes and/or eyelids, especially sensitive eyes and eyelids.
摘要翻译：影响哺乳动物，特别是人类患者的眼睛和/或睑板瘙痒和/或眼睛和/或睑部疼痛和/或眼睑和/或睑部麻醉感受物通过向该患者施用治疗/化妆有效量的至少一种 CGRP拮抗剂，有利地与除CGRP以外的神经肽的至少一种拮抗剂（例如物质P拮抗剂）和/或至少一种炎症介质拮抗剂的组合性混合物中; 主题组合物也非常适合于补充和/或照顾人眼，睫毛和/或眼睑，特别是敏感的眼睛和眼皮。

6. 发明授权

US5858024A Composition for dyeing keratin fibres containing a substance P antagonist 失效
标题翻译：用于染色含有P物质拮抗剂的角蛋白纤维的组合物
公开(公告)号：US5858024A
公开(公告)日：1999-01-12
申请号：US716534
申请日：1996-09-19
申请人： Olivier De Lacharriere , Lionel Breton , Genevieve Loussouarn
发明人： Olivier De Lacharriere , Lionel Breton , Genevieve Loussouarn
IPC分类号： A61K8/00 , A61K8/19 , A61K8/20 , A61K8/31 , A61K8/33 , A61K8/41 , A61K8/49 , A61K8/64 , A61K8/97 , A61K8/99 , A61Q5/00 , A61Q5/10 , A61K7/13
CPC分类号： A61K8/20 , A61K8/64 , A61K8/97 , A61K8/99 , A61Q5/10 , A61K2800/70
摘要： The invention relates to a composition, in particular a cosmetic composition, and more particularly one for dyeing keratin fibers, this composition containing at least one substance P antagonist in order to reduce or even eliminate the irritant effects of the dyes and/or pigments and/or dye precursors used during this dyeing. The substance P antagonist may form part of the dye composition itself or may be contained in a composition which is applied prior to the application of the dye composition.
摘要翻译：本发明涉及一种组合物，特别是化妆品组合物，更特别地涉及用于染色角蛋白纤维的组合物，该组合物含有至少一种物质P拮抗剂，以减少或甚至消除染料和/或颜料的刺激性影响和/ 或在染色期间使用的染料前体。物质P拮抗剂可以形成染料组合物本身的一部分，或者可以包含在施用染料组合物之前施用的组合物中。

7. 发明授权

US5851556A Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained 失效
标题翻译：在局部组合物和组合物中使用碱土金属盐作为TNF-A或物质P抑制剂
公开(公告)号：US5851556A
公开(公告)日：1998-12-22
申请号：US630326
申请日：1996-04-10
申请人： Lionel Breton , Olivier De Lacharriere
发明人： Lionel Breton , Olivier De Lacharriere
IPC分类号： A61K8/19 , A61K8/36 , A61K8/365 , A61K8/44 , A61K33/00 , A61K33/06 , A61K33/14 , A61Q19/00 , A61K33/32
CPC分类号： A61Q19/005 , A61K33/00 , A61K33/06 , A61K33/14 , A61K8/19 , A61K8/36 , A61K8/365 , A61K8/44 , A61Q19/00
摘要： The invention relates to the use of a salt of an alkaline-earth metal in a cosmetic, pharmaceutical, veterinary and/or dermatological composition for treating, in particular, sensitive skins. It relates, in addition, to the use of a salt of an alkaline-earth metal for preventing and/or combating rosacea and/or skin irritation and/or dartre and/or pudic erythema and/or dysesthetic sensation and/or sensation of inflammation and/or pruritus of the skin and/or of the mucous membranes. The salt is in particular strontium nitrate or chloride.
摘要翻译：本发明涉及在化妆品，药物，兽医和/或皮肤病学组合物中用于治疗特别是敏感皮肤的碱土金属盐的用途。此外，还涉及使用碱土金属的盐来预防和/或防治酒渣鼻和/或皮肤刺激和/或呕吐和/或红斑和/或躁动症和/或炎症感觉和/或皮肤和/或粘膜的瘙痒。该盐特别是硝酸锶或氯化锶。

8. 发明授权

US5788956A Antiperspirant compositions comprising substance P antagonists 失效
标题翻译：包含P物质拮抗剂的止汗剂组合物
公开(公告)号：US5788956A
公开(公告)日：1998-08-04
申请号：US738910
申请日：1996-10-28
申请人： Olivier De Lacharriere , Lionel Breton
发明人： Olivier De Lacharriere , Lionel Breton
IPC分类号： A61K8/19 , A61K8/20 , A61K8/64 , A61Q15/00 , A61K7/32 , A61K7/00
CPC分类号： A61K8/64 , A61K8/19 , A61K8/20 , A61Q15/00 , A61K2800/70
摘要： Cutaneous perspiration in a human subject is prevented and/or controlled by topically applying to the skin of an individual in need of such treatment, an effective antiperspirant amount of at least one substance P antagonist.
摘要翻译：通过局部施用于需要这种治疗的个体的皮肤，有效的止汗剂量的至少一种P物质拮抗剂来防止和/或控制人类受试者的皮肤出汗。

9. 发明授权

US5714155A Ethylenediamine derivative in a cosmetic or dermatological composition, and composition containing in particular a product having an irritant side effect 失效
标题翻译：化妆品或皮肤病学组合物中的乙二胺衍生物，特别是含有刺激性副作用的产品的组合物
公开(公告)号：US5714155A
公开(公告)日：1998-02-03
申请号：US575089
申请日：1995-12-19
申请人： Olivier De Lacharriere , Jean-Baptiste Galey , Lionel Breton , Jacqueline Dumats
发明人： Olivier De Lacharriere , Jean-Baptiste Galey , Lionel Breton , Jacqueline Dumats
IPC分类号： A61K9/06 , A61K8/00 , A61K8/04 , A61K8/30 , A61K8/41 , A61K8/49 , A61K9/08 , A61K9/107 , A61K9/127 , A61K31/135 , A61K31/137 , A61K31/275 , A61P17/00 , A61P43/00 , A61Q1/14 , A61Q5/02 , A61Q5/04 , A61Q5/08 , A61Q5/10 , A61Q9/04 , A61Q19/00 , A61Q19/08 , A61K7/48
CPC分类号： A61K31/137 , A61K8/41 , A61Q19/00 , A61K2800/75 , A61Q1/14 , A61Q19/004 , A61Q19/08 , A61Q5/02 , Y10S514/844 , Y10S514/846 , Y10S514/937 , Y10S514/938 , Y10S514/944
摘要： The invention relates to the use of an ethylenediamine derivative as a substance P antagonist and/or as a local analgesic in, or for the preparation of, a cosmetic or dermatological composition for treating sensitive skin-types. The invention relates in particular to the use of this derivative for preventing and/or combating skin irritations and/or dartres and/or erythema and/or dysaesthesic sensations and/or sensations of inflammation and/or pruritus of the skin and/or the mucous membranes including the eyes. The invention also relates to a composition containing a product having an irritant side effect and this derivative, so as to reduce this irritant effect or even to remove it altogether.
摘要翻译：本发明涉及乙二胺衍生物作为物质P拮抗剂和/或局部止痛剂在制备化妆品或皮肤病学组合物中用于治疗敏感性皮肤类型的用途。本发明特别涉及用于预防和/或防治皮肤刺激和/或眩晕和/或皮肤和/或粘液的炎症和/或瘙痒的红斑和/或呼吸困难感和/或感觉的用途。膜包括眼睛。本发明还涉及含有具有刺激性副作用的产品和该衍生物的组合物，以减少这种刺激性的影响，甚至完全去除它。

10. 发明申请

US20090275033A1 Uses of BNIPXL-Beta in premature canities 失效
标题翻译： BNIPXL-Beta在早产儿中的应用
公开(公告)号：US20090275033A1
公开(公告)日：2009-11-05
申请号：US12387138
申请日：2009-04-28
申请人： Bruno Bernard , Stephane Commo , Olivier De Lacharriere
发明人： Bruno Bernard , Stephane Commo , Olivier De Lacharriere
IPC分类号： C12Q1/68 , C07K14/00 , C07H21/02 , C12Q1/00 , G01N33/68 , G01N33/566
CPC分类号： C07K14/4747 , A61K8/64 , A61Q5/00
摘要： The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides.The invention also concerns methods for screening molecules modulating the expression of a gene coding for BNIPXL-beta and molecules modulating the activity of the BNIPXL-beta polypeptide, in order to identify an agent for use for cosmetic or therapeutic purposes in the field of pigmentation. The invention also encompasses various uses of molecules which may be identified by these methods.
摘要翻译：本发明涉及包含与全部或部分BNIPXLβ具有至少90％同一性的序列用于化妆品或治疗应用的多肽在治疗或预防人类早衰症中的用途，所述部分包含至少30个氨基酸以及用于相同目的的包含与BNIPXLβ的全部或部分cDNA序列具有至少90％同一性的RNAi序列的分子，所述部分包含至少18个核苷酸。本发明还涉及用于筛选调节编码BNIPXL-β的基因的表达的调节分子和调节BNIPXL-β多肽的活性的分子的方法，以鉴定在色素沉着领域中用于化妆品或治疗目的的药剂。本发明还包括可以通过这些方法鉴定的分子的各种用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式